ATE290089T1 - Methode zur verstärkung der biologischen aktivität von liganden - Google Patents

Methode zur verstärkung der biologischen aktivität von liganden

Info

Publication number
ATE290089T1
ATE290089T1 AT99968956T AT99968956T ATE290089T1 AT E290089 T1 ATE290089 T1 AT E290089T1 AT 99968956 T AT99968956 T AT 99968956T AT 99968956 T AT99968956 T AT 99968956T AT E290089 T1 ATE290089 T1 AT E290089T1
Authority
AT
Austria
Prior art keywords
polypeptide ligands
fusion polypeptide
ligands
enhancing
biological activity
Prior art date
Application number
AT99968956T
Other languages
English (en)
Inventor
Samuel J Davis
Nicholas W Gale
George D Yancopoulos
Neil Stahl
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE290089T1 publication Critical patent/ATE290089T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99968956T 1998-12-23 1999-12-23 Methode zur verstärkung der biologischen aktivität von liganden ATE290089T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11338798P 1998-12-23 1998-12-23
PCT/US1999/030900 WO2000037642A1 (en) 1998-12-23 1999-12-23 Method of enhancing the biological activity of ligands

Publications (1)

Publication Number Publication Date
ATE290089T1 true ATE290089T1 (de) 2005-03-15

Family

ID=22349103

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99968956T ATE290089T1 (de) 1998-12-23 1999-12-23 Methode zur verstärkung der biologischen aktivität von liganden

Country Status (12)

Country Link
US (1) US7008781B1 (de)
EP (1) EP1141294B1 (de)
JP (1) JP4493854B2 (de)
AT (1) ATE290089T1 (de)
AU (1) AU776393B2 (de)
CA (1) CA2354846A1 (de)
DE (1) DE69924009T2 (de)
HK (1) HK1040093B (de)
IL (1) IL143558A0 (de)
NZ (1) NZ512326A (de)
PL (1) PL199645B1 (de)
WO (1) WO2000037642A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9901428D0 (sv) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
WO2001047951A2 (en) * 1999-12-23 2001-07-05 An-Go-Gen Inc. Angiopoietin analogs
JP2004520009A (ja) * 2000-08-08 2004-07-08 エム．ジー．ヴィ．エス． リミテッド 核酸構築物、それにより形質転換された血管細胞、血管形成を誘発するためのそれを用いた医薬組成物および方法
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
GB0201679D0 (en) * 2002-01-25 2002-03-13 Asterion Ltd Polypeptide variants
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2008100288A2 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
US8957022B2 (en) 2006-10-27 2015-02-17 Sunnybrook Health Sciences Centre Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
WO2009158432A2 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
DK2714738T3 (en) 2011-05-24 2019-01-28 Zyngenia Inc MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
CA2909080C (en) 2013-04-11 2022-07-26 Sunnybrook Research Institute Methods, uses and compositions of tie2 agonists
CA2928852A1 (en) 2013-11-01 2015-05-07 Regeneron Pharmaceuticals, Inc. Angiopoietin-based interventions for treating cerebral malaria
WO2017079556A1 (en) 2015-11-06 2017-05-11 Regeneron Pharmaceuticals, Inc. Use of angiopoietins in promoting blood coagulation and in the treatment of blood coagulation disorders
KR101685532B1 (ko) * 2016-04-26 2016-12-13 한국프라임제약주식회사 혈관내피성장인자 수용체 융합단백질

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0547163B1 (de) 1990-08-29 2002-02-06 Centre Hospitalier Regional De Nantes An stabile proteinkernstruktur gebundene proteinpolyliganden
US5401650A (en) * 1990-10-24 1995-03-28 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-galactosidase A
FI952328A7 (fi) 1992-11-13 1995-07-10 Amgen Inc eck-respetorin lignandeja
US5747033A (en) 1993-10-28 1998-05-05 Regeneron Pharmaceuticals, Inc. Method of enhancing the biological activity of Eph family ligands
US5643755A (en) 1994-10-07 1997-07-01 Regeneron Pharmaceuticals Inc. Nucleic acid encoding tie-2 ligand
US5879672A (en) 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
DE69529674T3 (de) 1994-04-04 2007-06-28 Regeneron Pharmaceuticals, Inc. Biologisch aktive liganden der eph-familie
US5650490A (en) 1994-10-07 1997-07-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 2
US5814464A (en) 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
CA2216963C (en) 1995-04-06 2010-06-22 Regeneron Pharmaceuticals, Inc. Tie-2 ligands, methods of making and uses thereof
WO1996037621A2 (en) * 1995-05-23 1996-11-28 Morphosys Gesellschaft Für Proteinoptimierung Mbh Multimeric proteins
DE69635667T2 (de) 1995-10-25 2006-09-07 Regeneron Pharmaceuticals, Inc. Biologisch aktive liganden der eph familie
EP0861894B1 (de) * 1995-11-17 2006-03-08 Asahi Kasei Kabushiki Kaisha Polypeptid, das die differenzierung unterdrueckt
US5814478A (en) 1995-12-15 1998-09-29 Regeneron Pharmaceuticals, Inc. Tyrosine kinase receptors and ligands
CA2213512A1 (en) 1995-12-22 1997-07-03 Toray Industries, Inc. Method for producing bioactive fusion protein
US5851797A (en) 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
PT939809E (pt) 1996-06-19 2003-08-29 Regeneron Pharma Ligandos do receptor de tie-2 (ligando 3 de tie e ligando 4 de tie) e suas utilizacoes
US6265564B1 (en) 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule

Also Published As

Publication number Publication date
WO2000037642A1 (en) 2000-06-29
EP1141294B1 (de) 2005-03-02
HK1040093B (en) 2005-05-06
AU776393B2 (en) 2004-09-09
JP2003506008A (ja) 2003-02-18
HK1040093A1 (en) 2002-05-24
PL199645B1 (pl) 2008-10-31
WO2000037642A9 (en) 2000-11-02
DE69924009D1 (de) 2005-04-07
IL143558A0 (en) 2002-04-21
DE69924009T2 (de) 2006-04-13
EP1141294A1 (de) 2001-10-10
JP4493854B2 (ja) 2010-06-30
NZ512326A (en) 2003-11-28
CA2354846A1 (en) 2000-06-29
AU2714700A (en) 2000-07-12
US7008781B1 (en) 2006-03-07
PL349158A1 (en) 2002-07-01

Similar Documents

Publication Publication Date Title
DE69924009D1 (de) Methode zur verstärkung der biologischen aktivität von liganden
CY1108175T1 (el) ΠΟΛΥΠΕΠΤΙΔΙΟ DcR3, ΟΜΟΛΟΓΟ TNFR
ATE255420T1 (de) Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung
DE3280479D1 (de) Rekombinante DNS-Mittel und Verfahren
ATE212059T1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
DE69534588D1 (de) Protocadherin-proteine und verwendungen davon
IL130403A (en) Oil bodies and associated proteins as affinity matrices
ATE135371T1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
ATE522609T1 (de) Neurotrophe faktoren
FI104180B1 (fi) Menetelmä polypeptidin vasta-aineen ekä IL-4 välittämien tilojen hoitoon tarkoitetun seoksen valmistamiseksi
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
ATE328101T1 (de) Strukturprotein von adeno-assoziiertem virus mit veränderten chromatographischen eigenschaften
DE3177260D1 (de) Fuer plasminogen-aktivator kodierende rekombinante desoxyribonukleinsaeure und verfahren zur herstellung von plasminogen-aktivator-protein daraus.
EA200300708A1 (ru) Способы получения мультимерных белков и относящиеся к ним композиции
DE69534551D1 (de) Neue methode zum auffindenund bewerten biologisch aktiver moleküle
RU2007142191A (ru) Варианты бета-цепи hgf
SE8801701D0 (sv) Production technology based on enzymic method
ATE265226T1 (de) Verwendung von wolinella succinogenes asparaginase zur behandlung von asparagin- abhängiger krankheiten
DE69737651D1 (de) Cortistatin: neuropeptide, zusammensetzungen und methoden
ATE525390T1 (de) Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
WO1994026891A3 (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
DE69826493D1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
IL113252A0 (en) Eph receptors binding ligands
ATE443761T1 (de) Rtd receptor
DE68917154D1 (de) C-terminus-amidierungsenzym-zusammensetzung, verfahren zur herstellung und verwendung.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1141294

Country of ref document: EP